Baseline characteristics of patients with relapsing multiple sclerosis in asclepios phase 3 trials of ofatumumab versus teriflunomide

The requested reference [3c1707d671559dfddf9ed71be64c13312435c3fc] no longer exists in our database. It has been replaced by the current reference: [fde269c4f9d23309a7c8661b20db7ff5e6fcaa80]

Authors
Category Primary study
JournalNeurology
Year 2019
This article has no abstract
Epistemonikos ID: aafeaee952205b835c1825b88effcc62d97eb40d
First added on: Feb 11, 2025